SPRY
ARS Pharmaceuticals, Inc.
Key Financials
Revenue
$84.3M
↓ 5.5%
Operating Income
$-179448000
↓ 5720.6%
Net Income
$-171298000
↓ 2241.8%
EPS (Diluted)
$-1.74
↓ 2275.0%
Cash & Equivalents
$41.3M
↓ 18.7%
Total Liabilities
$213.4M
↑ 126.2%
Total Assets
$327.7M
↓ 6.7%
Long-term Debt
$96.4M
↑ Infinity%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 10/5/2026 | View on SEC |
| 144 | 10/1/2026 | View on SEC |
| 144 | 9/30/2026 | View on SEC |
| 144 | 9/11/2026 | View on SEC |
| 144 | 9/11/2026 | View on SEC |
| 144 | 9/4/2026 | View on SEC |
| 144 | 9/3/2026 | View on SEC |
| 4 | 9/2/2026 | View on SEC |
| 144 | 9/2/2026 | View on SEC |
| 144 | 9/1/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | SPRY |
| Company Name | ARS Pharmaceuticals, Inc. |
| CIK | 1671858 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 858-771-9307 |